LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

AbCellera Biologics Inc

Cerrado

SectorSalud

4.74 8.97

Resumen

Variación precio

24h

Actual

Mínimo

4.35

Máximo

4.84

Métricas clave

By Trading Economics

Ingresos

11M

-35M

Ventas

13M

17M

Margen de beneficio

-203.272

Empleados

596

EBITDA

769K

-39M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+111.49% upside

Dividendos

By Dow Jones

Próximas Ganancias

3 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-49M

1.2B

Apertura anterior

-4.23

Cierre anterior

4.74

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

346 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 sept 2025, 17:03 UTC

Principales Movimientos del Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept 2025, 16:49 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

GD Culture Shares Drop After Deal for Pallas Capital

16 sept 2025, 16:11 UTC

Principales Movimientos del Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept 2025, 23:40 UTC

Charlas de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept 2025, 23:20 UTC

Charlas de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept 2025, 21:10 UTC

Adquisiciones, fusiones, absorciones

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept 2025, 20:51 UTC

Charlas de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 20:25 UTC

Ganancias

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept 2025, 20:24 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept 2025, 19:19 UTC

Charlas de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept 2025, 18:52 UTC

Charlas de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept 2025, 18:40 UTC

Adquisiciones, fusiones, absorciones

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept 2025, 18:38 UTC

Charlas de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept 2025, 18:19 UTC

Charlas de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept 2025, 18:01 UTC

Charlas de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept 2025, 17:34 UTC

Charlas de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept 2025, 16:53 UTC

Ganancias

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 16:15 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Commodities Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Energy Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept 2025, 15:22 UTC

Charlas de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept 2025, 15:21 UTC

Charlas de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

111.49% repunte

Estimación a 12 meses

Media 9.2 USD  111.49%

Máximo 17 USD

Mínimo 5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

346 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat